New Agents for Recurrent Follicular Lymphoma
00:16:50

New Agents for Recurrent Follicular Lymphoma

In this presentation from "Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies", Dr. Sven de Vos disuccese new agents for use in the treatment of recurrent follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

594 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Trending

Probiotics: changing the way we perceive them
00:01:36

Probiotics: changing the way we perceive them
570 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Intestinal Tumor Commonly Asked Questions
0:03:59

Intestinal Tumor Commonly Asked Questions
5 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Rituximab Maintenance for Follicular Lymphoma CAR-T Trial salvages Primary, Refractory, or those who failed initial therapy
00:01:43

Rituximab Maintenance for Follicular Lymphoma CAR-T Trial salvages Primary, Refractory, or those who failed initial therapy
90 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
New Insights on Acquired Resistance to Immune Checkpoint Inhibitors for NSCLC: Implications for Treatment Options (BMIC-028)
00:11:34

New Insights on Acquired Resistance to Immune Checkpoint Inhibitors for NSCLC: Implications for Treatment Options (BMIC-028)
235 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
A next-generation CD33-directed ADC for AML
00:00:45

A next-generation CD33-directed ADC for AML
115 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
SABRINA: Phase 3 study comparing subcutaneous and intravenous rituximab in follicular lymphoma | Dr Andrew Davies at EHA 2015
00:01:32

SABRINA: Phase 3 study comparing subcutaneous and intravenous rituximab in follicular lymphoma | Dr Andrew Davies at EHA 2015
3,380 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Does CLL Return More Aggressively After Relapse?
00:01:13

Does CLL Return More Aggressively After Relapse?
396 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Radiolabeled CD45 in Stem Cell Transplant For High Risk Multiple Myeloma
00:01:15

Radiolabeled CD45 in Stem Cell Transplant For High Risk Multiple Myeloma
107 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Promising Data for Treatment of Liver Cancer (HCC and iCCA) at Annual Meeting 2017
00:04:07

Promising Data for Treatment of Liver Cancer (HCC and iCCA) at Annual Meeting 2017
956 Views
2 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
ADD-What is the latest on a new drug called selinexor
00:04:07

ADD-What is the latest on a new drug called selinexor
158 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Developing a self-management programme to support prostate and testicular cancer survivors | Dr Andrew Turner at UKONS 2015
00:03:10

Developing a self-management programme to support prostate and testicular cancer survivors | Dr Andrew Turner at UKONS 2015
338 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
ELIQUIS(Apixaban) In Non Cancer Setting
00:01:40

ELIQUIS(Apixaban) In Non Cancer Setting
189 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Latest Videos

Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
0:16:51

Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
1 Views
4 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Perspectives on the Future of CML
0:26:35

Perspectives on the Future of CML
0 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease

2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease
1 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Re-evaluating TKI in CML Patients During Pregnancy
0:15:04

Re-evaluating TKI in CML Patients During Pregnancy
0 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
2 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CML and Pregnancy
0:15:30

CML and Pregnancy
1 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Acute Lymphoblastic Leukemia

2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease

2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease
1 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019

INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
2 Views
6 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase 1/2 AUGMENT-101 Trial @sloan_kettering
0:04:52

Phase 1/2 AUGMENT-101 Trial @sloan_kettering
12 Views
2 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Melanoma Rates Decline Found in Younger Population
0:03:21

Melanoma Rates Decline Found in Younger Population
2 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
12 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
EE:EE:EE

What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
38 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Acute Myelogenous Leukemia

Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
2 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
5 Views
5 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
15 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
How to Manage MDS Patients who are Ineligible for Transplant
00:01:47

How to Manage MDS Patients who are Ineligible for Transplant
300 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The Recent Wave of Approval in AML
00:01:54

The Recent Wave of Approval in AML
138 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Updated Data on Gilteritinib in AML
00:01:12

Updated Data on Gilteritinib in AML
16 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Bladder Cancer

EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
0:02:13

EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
17 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
EV-103 Phase I Trial Presented at #ESMO19
0:01:45

EV-103 Phase I Trial Presented at #ESMO19
24 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
33 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer

Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
23 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Strategies for Treating 2nd Line RCC Patients
00:01:17

Strategies for Treating 2nd Line RCC Patients
54 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Treating Newly Diagnosed RCC Patients
00:02:08

Treating Newly Diagnosed RCC Patients
53 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Bone Metastases

If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open is a Great Idea
00:00:40

If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open is a Great Idea
194 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Brain Cancer

Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
5 Views
2 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Predicting Tumor Recurrence: How Does This Help Us?
0:03:05

Predicting Tumor Recurrence: How Does This Help Us?
7 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Predicting Tumor Recurrence
0:03:36

Predicting Tumor Recurrence
20 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
How does this affect clinicians today?
0:01:20

How does this affect clinicians today?
7 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
0:01:26

Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
15 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Oncoceutics Commemorates National Childhood Cancer Awareness Month

Oncoceutics Commemorates National Childhood Cancer Awareness Month
14 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Breast Cancer

CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial

CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
6 Views
5 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Is This Going To Affect Survival? @DukeCancer @DrLolaFayanju
0:03:14

Is This Going To Affect Survival? @DukeCancer @DrLolaFayanju
2 Views
1 week ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Radiation After Breast Cancer Diagnosis @DukeCancer @DrLolaFayanju
0:02:49

Radiation After Breast Cancer Diagnosis @DukeCancer @DrLolaFayanju
4 Views
1 week ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Who is Eligible for the AVIATOR Study? @SeattleCCA
0:02:08

Who is Eligible for the AVIATOR Study? @SeattleCCA
2 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The AVIATOR Study @SeattleCCA
0:04:33

The AVIATOR Study @SeattleCCA
3 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer
8 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Business Management

Two Sided Payment Agreements & The Risks Involved
00:01:47

Two Sided Payment Agreements & The Risks Involved
116 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
MOASC COAnalyzer Tool Ricky Newton
01:01:00

MOASC COAnalyzer Tool Ricky Newton
99 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Cervical Cancer

Novel revelations in CLL biology with venetoclax/ibrutinib
00:02:24

Novel revelations in CLL biology with venetoclax/ibrutinib
93 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immunotherapy in gynecological cancers: current and future landscape
00:02:35

Immunotherapy in gynecological cancers: current and future landscape
474 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Chronic Lymphocytic Leukemia

New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...

New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
2 Views
6 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase 3 DUO Study @ospniguarda
0:11:36

Phase 3 DUO Study @ospniguarda
9 Views
2 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
ASH 2016 Page 3 Maintenance Therapy in Chronic Lymphocytic Leukemia
00:04:47

ASH 2016 Page 3 Maintenance Therapy in Chronic Lymphocytic Leukemia
201 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
ASH 2016 Page 2 Update on New Chronic Lymphocytic Leukemia Drugs
00:07:04

ASH 2016 Page 2 Update on New Chronic Lymphocytic Leukemia Drugs
92 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CLL, What is the significance of IGHV mutations and how are they assessed
00:02:48

CLL, What is the significance of IGHV mutations and how are they assessed
87 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Not Your Fathers CLL with Dr. John Pagel
01:02:14

Not Your Fathers CLL with Dr. John Pagel
114 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Chronic Myelogenous Leukemia

Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
0:16:51

Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
1 Views
4 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Perspectives on the Future of CML
0:26:35

Perspectives on the Future of CML
0 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Re-evaluating TKI in CML Patients During Pregnancy
0:15:04

Re-evaluating TKI in CML Patients During Pregnancy
0 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CML and Pregnancy
0:15:30

CML and Pregnancy
1 Views
5 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Treating CML & Myelofibrosis Patients
00:01:34

Treating CML & Myelofibrosis Patients
319 Views
11 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Resistance/intolerance to second generation TKIs in CML: what to do next?
00:02:14

Resistance/intolerance to second generation TKIs in CML: what to do next?
155 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Colorectal Cancer

Are These Gene Fusions Targetable? @katherineclift4 @WUSTL
0:02:35

Are These Gene Fusions Targetable? @katherineclift4 @WUSTL
3 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Anti-EGFR Resistance Mechanism Using Tumor DNA Assay @katherineclift4 @WUSTL
0:07:15

Anti-EGFR Resistance Mechanism Using Tumor DNA Assay @katherineclift4 @WUSTL
23 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
BEACON Trial: What's Next?
0:02:57

BEACON Trial: What's Next?
11 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase 3 BEACON CRC Trial
0:04:43

Phase 3 BEACON CRC Trial
70 Views
1 month ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic ...

Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic ...
30 Views
2 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login